1Grundy S M. Cholesterol and coronary heart disease: anew era[J]. J Am Med Assoc, 1986, 256 (20): 2849-2858.
2Thelle D S. Hypercholesterolaemia[J]. Drug Invest, 1990, 2 (2): 1-8.
3Cheng L P, Huang X Y, Wang Z, et al. Combined 3D-QSAR, molecular docking, and molecular dyna- mics study on potent cyclohexene-based influenza neuraminidase inhibitors[J]. Monatsh Chem, 2014, 145(7): 1213-1225.
4Wang Z, Cheng L P, Kai Z P, et al. Molecular modeling studies of atorvastatin analogues as HMGR inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations [ J ]. Bioorg Med Chem Lett, 2014, 24(16): 3869-3876.
5Pfefferkorn J A, Choi C, Song Y T, et al. Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhihitors [J]. Bioorg Med Chem Lett, 2007, 17(16): 4531-4537.
6Pfefferkorn J A, Song Y T, Sun K L, et al. Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors [J]. Bioorg Med Chem Lett, 2007, 17(16): 4538-4544.
7Bratton L D, Auerbach B, Choi C, et al. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reduetase[J]. Bioorg Med Chem, 2007, 15(16): 5576-5589.
8Clark M, Cramer R D, Van Opdenbosch D, et al. Validation of the general purpose tripos 5. 2 force field[J]. J Comput Chem, 1989, 10(8): 982-1012.
9Gasteiger J, Marsili M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic eharges[J]. Tetrahedron, 1980, 36(22): 3219-3228.
10Abdulhameed M D M, Hamza A, Liu J J, et al. Combined 3D-QSAR modeling and molecular docking study on indolinonederivativesasinhibitors of 3-phos- phoinositide-dependent protein kinase-1[J]. J Chem Inf Model, 2008, 48(9): 1760-1772.
